Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda clinical programs — 335 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Cambridge, USA
Founded
1993
Employees
1,617
Programs
1179
Drugs
359
Patents
1436
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Takeda projects

335 ClinicalTrials.gov programs sponsored by Takeda.

Takeda has 335 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

335 programs

Clinical programs

Page 1 of 7

  1. 01-02-TL-375-015

    Takeda

    Drug Abuse

    phase 2 small molecule completed

    1 trial

  2. 160001

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 2 small molecule completed

    1 trial

  3. 160002

    Takeda

    Immune Thrombocytopenic Purpura (ITP)

    phase 2 small molecule completed

    1 trial

  4. 75mg SHP647 (PF-00547659)

    Takeda

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  5. 851B

    Takeda

    Papillomavirus Infections

    phase 2 small molecule terminated

    2 trials

  6. ADCETRIS 50 mg powder for concentrate for solution for infusion

    Takeda

    Hodgkin lymphoma (HL) - Hodgkin lymphoma (HL), a neoplasm of lymphoid tissue which is histopathologically defined by the presence of malignant Hodgkin Reed-Sternberg (HRS) cells in a background of inflammatory cells. The proposed pediatric study has been designed to evaluate brentuximab vedotin as a component of a multiagent frontline chemotherapy regimen in patients with advanced stage, newly diagnosed HL, here defined as Stage III and Stage IV and a ≥50 Lansky Play-Performance or Karnofsky Performance Status.

    phase 2 small molecule active

    1 trial

  7. ALX-0600

    Takeda

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  8. ALX1-11 50 mcg

    Takeda

    Osteoporosis

    phase 2 small molecule completed

    1 trial

  9. AMG 706

    Takeda

    Advanced Gastrointestinal Stromal Tumor

    phase 2 small molecule completed

    1 trial

  10. AP24534-14-203

    Takeda

    Chronic Phase Chronic Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  11. Adcetris-Levact

    Takeda

    Clinical Efficacy

    phase 2 small molecule completed

    1 trial

  12. Aerosolized, Recombinant Alpha 1-Antitrypsin

    Takeda

    Alpha1-antitrypsin Deficiency

    phase 2 small molecule completed

    2 trials

  13. Aes-103

    Takeda

    Sickle Cell Disease

    phase 2 small molecule completed

    2 trials

  14. Alisertib

    Takeda

    Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  15. Alisertib

    Takeda

    Ovarian Carcinoma

    phase 2 small molecule completed

    2 trials

  16. Alisertib

    Takeda

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  17. Alisertib

    Takeda

    Adenocarcinoma of the Prostate

    phase 2 small molecule completed

    1 trial

  18. Alisertib

    Takeda

    Acute Myelogenous Leukemia

    phase 2 small molecule completed

    1 trial

  19. Alisertib

    Takeda

    Diffuse Large B-cell Lymphoma

    phase 2 small molecule completed

    1 trial

  20. Alisertib (MLN8237)

    Takeda

    Diffuse Large B-Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  21. AskBio009

    Takeda

    Hemophilia B

    phase 2 mab active

    1 trial

  22. Azacitidine

    Takeda

    Myelodysplastic Syndromes

    phase 2 small molecule completed

    2 trials

  23. Azilsartan

    Takeda

    Hypertension

    phase 2 small molecule completed

    2 trials

  24. B-MAD chemotherapy

    Takeda

    Extranodal NK/T-cell Lymphoma

    phase 2 small molecule completed

    1 trial

  25. BAX 888

    Takeda

    Hemophilia A

    phase 2 small molecule completed

    1 trial

  26. BAX69 + infusional 5-FU/LV

    Takeda

    Metastatic Colorectal Cancer

    phase 2 mab terminated

    1 trial

  27. BAX69 Single-Route Arm

    Takeda

    Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites

    phase 2 mab terminated

    1 trial

  28. Blinatumomab

    Takeda

    Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

    phase 2 mab active

    1 trial

  29. Bortezomib

    Takeda

    Plasma Cell Myeloma

    phase 2 small molecule active

    1 trial

  30. Bortezomib

    Takeda

    Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)

    phase 2 small molecule completed

    1 trial

  31. Bortezomib

    Takeda

    Recurrent Plasma Cell Myeloma

    phase 2 small molecule active

    1 trial

  32. Brentuximab Vedotin

    Takeda

    Hodgkin Disease

    phase 2 small molecule active

    2 trials

  33. Brentuximab Vedotin

    Takeda

    Enteropathy Associated T-cell Lymphoma

    phase 2 small molecule completed

    1 trial

  34. Brentuximab Vedotin in Combination with Tislelizumab

    Takeda

    NK/T Cell Lymphoma Nos

    phase 2 small molecule active

    1 trial

  35. Brentuximab vedotin

    Takeda

    Relapsed or Refractory Hodgkin Lymphoma

    phase 2 small molecule completed

    1 trial

  36. BrentuximabVedotin (BV)

    Takeda

    Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  37. Brigatinib

    Takeda

    NSCLC, Stage III

    phase 2 small molecule terminated

    1 trial

  38. Brigatinib

    Takeda

    NSCLC

    phase 2 small molecule active

    1 trial

  39. Brigatinib

    Takeda

    Neurofibromatosis Type 2

    phase 2 small molecule active

    1 trial

  40. Brigatinib

    Takeda

    Lymphoma, Large-Cell, Anaplastic

    phase 2 small molecule completed

    1 trial

  41. Brigatinib

    Takeda

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule completed

    1 trial

  42. Brigatinib

    Takeda

    Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma

    phase 2 small molecule terminated

    1 trial

  43. Brigatinib

    Takeda

    Anaplastic Large Cell Lymphoma, ALK-Positive

    phase 2 small molecule active

    1 trial

  44. Brigatinib

    Takeda

    ALK-positive Advanced NSCLC

    phase 2 small molecule completed

    2 trials

  45. C1 Esterase Inhibitor Injection [Cinryze]

    Takeda

    Subarachnoid Hemorrhage, Aneurysmal

    phase 2 small molecule active

    1 trial

  46. C1 Inhibitor, Human

    Takeda

    Traumatic Brain Injury

    phase 2 small molecule active

    1 trial

  47. CINRYZE

    Takeda

    Hereditary Angioedema

    phase 2 mab completed

    1 trial

  48. CINRYZE

    Takeda

    Hereditary Angioedema (HAE)

    phase 2 mab completed

    1 trial

Frequently asked questions

How many clinical projects does Takeda have?

335 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.